News DXcellence12, a Fully Automated Sample-to-Answer Molecular Diagnostics Platform from Accunome Sciences, Received NMPA Approval of Class III Registration in ChinaFully Automated Sample-to-Answer Molecular Diagnostics Platform (DXcellence12) and Three Diagnostics Kits from Accunome Sciences Have Obtained CE Mark CertificationAccunome Science Has Raised A Total of More Than 100 million RMB of Financing to Accelerate Its Commercialization Previous Next DXcellence12, a Fully Automated Sample-to-Answer Molecular Diagnostics Platform from Accunome Sciences, Received NMPA Approval of Class III Registration in China Read More » Accunome Science Has Raised A Total of More Than 100 million RMB of Financing to Accelerate Its Commercialization Read More » Fully Automated Sample-to-Answer Molecular Diagnostics Platform (DXcellence12) and Three Diagnostics Kits from Accunome Sciences Have Obtained CE Mark Certification Read More » More News
DXcellence12, a Fully Automated Sample-to-Answer Molecular Diagnostics Platform from Accunome Sciences, Received NMPA Approval of Class III Registration in China Read More »
Accunome Science Has Raised A Total of More Than 100 million RMB of Financing to Accelerate Its Commercialization Read More »
Fully Automated Sample-to-Answer Molecular Diagnostics Platform (DXcellence12) and Three Diagnostics Kits from Accunome Sciences Have Obtained CE Mark Certification Read More »
